

**MASSACHUSETTS
ADULT
IMMUNIZATION
COALITION
MEETING**

Tuesday, January 25, 2022
6:30 – 8:30 PM



**Massachusetts
Adult Immunization
Coalition**



Agenda

- Laurie Courtney - COVID Vaccine Update
- Cynthia McReynolds - MA Vaccine Confidence Project update
- Amy Sgueglia - MA COVID-19 Mobile Vaccination Program
- New MAIC website update/preview
- 2022 MA Adult Immunization Conference update
- Updates from the Field
- Closing

COVID-19 Vaccine Updates

Laurie Courtney, RN

Massachusetts Department of Public Health



COVID-19 Vaccine Update

Laurie Courtney, Immunization Nurse Manager, MDPH
Laurie.A.Courtney@mass.gov

How are we doing in Massachusetts?

Numbers reported last week:

- 13,406,529 doses administered
- 5,172,580 fully vaccinated people
- 2,570,643 booster doses
- 188,468 doses administered in the last 7 days
- 20,377 people became fully vaccinated in the last 7 days
- 86% of the MA population (compared with 75% of US) has at least one dose
- 49% of MA (compared with 39% of US) has a booster dose

Recent Updated Recommendations

- December 16: CDC endorsed a clinical preference for individuals to receive an mRNA COVID-19 vaccine over Johnson & Johnson's COVID-19 vaccine
- January 4: CDC recommended:
 - Pfizer booster at 5 months
 - third primary dose for immunocompromised children ages 5-11
- January 5: CDC recommended boosters for ages 12-15
- January 7: CDC shortened interval for booster dose of Moderna COVID-19 vaccine to 5 months

Key Points

- A primary series is recommended for everyone ages 5 years and older
- An additional (third) primary series dose is recommended at least 28 days after dose #2 for moderately or severely immunocompromised people ages 5 years and older who received a 2-dose mRNA vaccine primary series.
- In most situations, Pfizer-BioNTech or Moderna are preferred over Janssen/J&J
- A booster dose is recommended for everyone ages 12 years and older (Pfizer for ages 12–17; an mRNA vaccine preferred for ages 18 years and older):
 - At least 5 months after completion of an mRNA vaccine
 - At least 2 months after completion of a Janssen/J&J primary dose.

Primary series

TABLE 1. COVID-19 vaccines: primary series and additional primary dose

Vaccine manufacturer	Age indication	Vial cap color denoting formulation	Dose	Injection volume	Number of doses in primary series (Interval between doses)	Additional primary dose in immunocompromised people (Interval since second dose)
Pfizer-BioNTech	5–11 years	Orange	10 µg	0.2 mL	2 (21 days)	1 (≥28 days)
Pfizer-BioNTech	≥12 years	Purple or gray	30 µg	0.3 mL	2 (21 days)	1 (≥28 days)
Moderna	≥18 years	Not applicable	100 µg	0.5 mL	2 (28 days)	1 (≥28 days)
Janssen	≥18 years	Not applicable	5×10 ¹⁰ viral particles	0.5 mL	1 (Not applicable)	Not applicable

Dec 16

mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for the prevention of COVID-19 for those ≥ 18 years of age

- In most situations, mRNA COVID-19 vaccines are **preferred** over the Janssen COVID-19 vaccine for primary and booster vaccination, including those who received Janssen COVID-19 vaccine for their single dose primary series
- Janssen COVID-19 vaccines may be offered to the following populations:
 - Persons with a contraindication to mRNA COVID-19 vaccines (e.g. severe allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine)
 - Persons who would otherwise remain unvaccinated for COVID-19 due to limited access to mRNA COVID-19 vaccines
 - Persons who would prefer the Janssen COVID-19 vaccine despite safety concerns identified
- Persons who elect to receive a Janssen COVID-19 vaccine should be informed, as part of the pre-vaccination discussion with the vaccine provider, about the **risk** and **symptoms of TTS** that could occur in the 2 weeks after vaccination, the need to seek **immediate medical care** should symptoms develop, and the **availability** of mRNA COVID-19 vaccines
- Vaccine providers should start the two-dose mRNA COVID-19 vaccine series, even if there is uncertainty about how the patient will receive their second dose; two-dose mRNA vaccines can be used in **any population or setting**
- It is **contraindicated** to administer Janssen COVID-19 vaccine to persons with a history of TTS following receipt of Janssen or other adenovirus vector-based COVID-19 vaccines (e.g. AstraZeneca's COVID-19 vaccine) **EUAs updated 12/14/2021**

Booster dose

TABLE 2. COVID-19 vaccines: booster dose by primary series

Vaccine completed for primary series	Authorized age for vaccine booster	Interval between last primary dose (including additional dose, when applicable) and booster dose	Number of doses	Injection volume and product that may be given as booster dose*†
Pfizer-BioNTech	≥12 years	≥5 months	1	0.3 mL Pfizer-BioNTech*, or 0.25 mL Moderna, or 0.5 mL Janssen†
Moderna	≥18 years	≥5 months	1	0.25 mL Moderna, or 0.3 mL Pfizer-BioNTech, or 0.5 mL Janssen†
Janssen	≥18 years	≥2 months	1	0.5 mL Janssen†, or 0.3 mL Pfizer-BioNTech, or 0.25 mL Moderna

*Only Pfizer BioNTech can be used as a booster dose in those ages 12–17 years.

†Use of an mRNA vaccine for a booster dose is preferred over Janssen vaccine.

Stay Up to Date with Your Vaccines

- Aligns with standard language CDC uses about other vaccinations
- CDC recommends individuals stay “up to date” by receiving any additional doses they are eligible for
- Definition of “fully vaccinated” – two doses of an mRNA vaccine or one dose of the Janssen/J&J vaccine – has not changed.
- Individuals are considered fully vaccinated 14 days after completion of a primary series
- A person is considered “boosted” and up to date right after getting their booster dose
- A person is considered “up to date” if they’ve received all doses recommended for them

People Vaccinated Outside the US

- [Emergency Use Instructions](#) (EUI) provide info on the use of the approved (licensed) Pfizer-BioNTech (Comirnaty) vaccine that extend beyond the FDA-approved labeling
- Heterologous use for persons ≥ 12 years, who received a vaccine listed for [emergency use by WHO](#), but is not FDA-approved or FDA-authorized:
 - As a primary dose in those with incomplete primary dose series
 - As an additional primary dose in those with certain immunocompromising conditions
 - As a booster dose, at least 5 months after receiving primary vaccination

Public Portal

My Vax Records

<https://myvaxrecords.mass.gov>

- Obtain your vaccination record from MIIS
- Includes all vaccines administered in MA/in MIIS
- Generate a COVID-19 digital vaccine card and QR code
- Save to a smartphone or computer, or print out



CDC COVID-19 Gateway webpages

[COVID-19 Vaccination](#)

Product Info by U.S. Vaccine

Interim Clinical Considerations


Clinical Care

Provider Requirements and Support

Training and Education

[COVID-19 Vaccination](#)

Clinical & Professional Resources



What's New

- [Resources to F Children and T](#)
- [School-Location Practices for S](#)
- [Quick Convers Vaccines for Cl](#)
- [How to Condu Assessment](#)

<https://www.cdc.gov/vaccines/covid-19/index.html>

COVID-19 Languages | ASL Videos | Easy to Read

Home | Your Health | Vaccines | Cases & Data | Work & School | Healthcare Workers | Health Depts | Science | More



Types of Masks and Respirators

CDC continues to recommend that you wear the most protective mask you can that fits well and that you will wear consistently.

[Learn More](#)

Highlights

- Quarantine & Isolation
- Omicron Variant
- Guidance for Schools
- Stay Up to Date with Your Vaccines

- GUIDANCE
- SCIENCE UPDATES
- HEALTHCARE WORKERS
- U.S. GOVERNMENT RESPONSE (USA.gov)


<https://www.cdc.gov/coronavirus/2019-ncov/index.html>

COVID-19 Vaccination Gateway Page Takes You To.....

🏠 COVID-19 Vaccination

Product Info by U.S. Vaccine	+	→	Vaccine specific info, standing orders, prep & admin summaries, EUAs, HCP Quick Reference Guide, screening form...
Interim Clinical Considerations	+	→	Clinical Guidance, anaphylaxis, myocarditis/pericarditis...
Clinical Care	+	→	Vaccinating special populations ...
Provider Requirements and Support	+		
Training and Education	+	→	Training module for each vaccine, core competencies, how to talk to patients/parents about COVID19 vaccines, resources...
Vaccine Recipient Education	+	→	How to talk to people about C-19 vaccines, dealing with misinformation...
Health Departments	+		
Planning & Partnerships	+		
Vaccine Effectiveness Research			
COVID-19 Vaccine Data Systems	+		
Content Syndication			
Vaccinate with Confidence	+		

COVID-19 Gateway Page Takes You To.....



Massachusetts Vaccine Confidence Project Update

Cynthia McReynolds, MBA
Immunization Initiative, MA Chapter,
American Academy of Pediatrics



MA Vaccine Confidence Project Update

- Resources and Communications
 - Branding, Logo, Website
- Outreach
- Collaborations
- Goals and Objectives
- Trainings and Cross Promotions of Vaccine Confidence



MA COVID-19 Mobile Vaccination Program Overview

Amy Sgueglia, MSN, RN
MAIC Facilitator



MA COVID-19 Mobile Vaccination Program

- Vaccine Provider will come to you
- Available for schools, community organizations, churches, colleges/universities
- 20 VEI communities are prioritized
- To request a clinic:
<https://www.mass.gov/info-details/covid-19-mobile-vaccination-program>

MAIC Website updates

- Preview new maic.jsi.com
- Launching Wednesday, January 26, 2022



2022 MA Adult Immunization Conference

- [Save the date](#): Tuesday, April 5, 2022, 8a-4p (Virtual)
- Keynote speakers:
 - Dr. Kevin Ault - University of Kansas Medical Center
 - Dr. Andrew Kroger - Centers for Disease Control
 - Dr. Sarah Oliver - ACIP COVID-19 Vaccines Work Group, CDC
 - Dr. Joe Smyser, Public Goods Project, Project VCTR
 - Pejman Talebian, MA Department of Public Health
- Website & registration to open 2nd wk in February
- Event Virtual Attendee Hub to open ~March 22nd
- Virtual Exhibitor Booths



Updates From The Field

- Flu Updates
- Manufacturer Updates
- Successes
- Challenges

Thank you!

Questions? Please contact:

Amy Sgueglia, MAIC Facilitator
amy_sgueglia@jsi.com

Alexandra Burke
Manager & Registrar, MA Adult Immunization Conference
alexandra_burke@jsi.com

